BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22956556)

  • 1. Seizures and type 1 diabetes mellitus: current state of knowledge.
    Verrotti A; Scaparrotta A; Olivieri C; Chiarelli F
    Eur J Endocrinol; 2012 Dec; 167(6):749-58. PubMed ID: 22956556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemic seizures and epilepsy in type I diabetes mellitus.
    Falip M; Miró J; Carreño M; Jaraba S; Becerra JL; Cayuela N; Perez Maraver M; Graus F
    J Neurol Sci; 2014 Nov; 346(1-2):307-9. PubMed ID: 25183236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti glutamate-decarboxylase antibodies: a liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus.
    Szűcs A; Barcs G; Winkler G; Soós Z; Folyovich A; Kelemen A; Várallyay P; Kamondi A
    Ideggyogy Sz; 2014 Jul; 67(7-8):269-71. PubMed ID: 25509368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy.
    Vincent A; Crino PB
    Epilepsia; 2011 May; 52 Suppl 3():12-7. PubMed ID: 21542840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications.
    Lilleker JB; Biswas V; Mohanraj R
    Seizure; 2014 Sep; 23(8):598-602. PubMed ID: 24836709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GAD-65 autoantibody associated epilepsy.
    Dimova R; Grozeva G; Chakarova N; Tsarkova P; Tankova T
    J Pediatr Endocrinol Metab; 2020 May; 33(6):817-820. PubMed ID: 32436860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
    Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
    Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamic acid decarboxylase autoantibodies and neurological disorders.
    Vianello M; Tavolato B; Giometto B
    Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus.
    Tsirogianni A; Pipi E; Soufleros K
    Autoimmun Rev; 2009 Jul; 8(8):687-91. PubMed ID: 19217947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes.
    Striano P; Perruolo G; Errichiello L; Formisano P; Beguinot F; Zara F; Striano S
    Ann Neurol; 2008 Jan; 63(1):127-8. PubMed ID: 17167787
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies.
    Vianello M; Keir G; Giometto B; Betterle C; Tavolato B; Thompson EJ
    Eur J Neurol; 2005 Apr; 12(4):294-9. PubMed ID: 15804247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electroencephalographic abnormalities in children with type 1 diabetes mellitus: a prospective study.
    Yildirim R; Günbey C
    Turk J Med Sci; 2023; 53(6):1794-1798. PubMed ID: 38813513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.
    Ali F; Rowley M; Jayakrishnan B; Teuber S; Gershwin ME; Mackay IR
    J Autoimmun; 2011 Sep; 37(2):79-87. PubMed ID: 21680149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of enterovirus infections, autoimmune factors and HLA genotypes in patients with T1DM.
    Çekin Y; Özkaya E; Gülkesen H; Akçurin S; Çolak D
    Minerva Endocrinol; 2014 Mar; 39(1):67-74. PubMed ID: 24513606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults.
    Jin P; Huang G; Lin J; Yang L; Xiang B; Zhou W; Zhou Z
    Clin Endocrinol (Oxf); 2011 May; 74(5):587-92. PubMed ID: 21470281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk of type 1 diabetes mellitus.
    Hatziagelaki E; Jaeger C; Petzoldt R; Seissler J; Scherbaum WA; Federlin K; Bretzel RG
    Horm Metab Res; 1999 Oct; 31(10):564-9. PubMed ID: 10596966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
    Daw K; Ujihara N; Atkinson M; Powers AC
    J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous triple organ specific autoantibody profiling in adult patients with type 1 diabetes mellitus and their first-degree relatives.
    Dagdelen S; Hascelik G; Bayraktar M
    Int J Clin Pract; 2009 Mar; 63(3):449-56. PubMed ID: 18218004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM).
    Karavanaki K; Kakleas K; Paschali E; Kefalas N; Konstantopoulos I; Petrou V; Kanariou M; Karayianni C
    Horm Res; 2009; 71(4):201-6. PubMed ID: 19258711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum antibodies in epilepsy and seizure-associated disorders.
    McKnight K; Jiang Y; Hart Y; Cavey A; Wroe S; Blank M; Shoenfeld Y; Vincent A; Palace J; Lang B
    Neurology; 2005 Dec; 65(11):1730-6. PubMed ID: 16344514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.